214 related articles for article (PubMed ID: 26261568)
1. Expression of the EphA1 protein is associated with Fuhrman nuclear grade in clear cell renal cell carcinomas.
Wang X; Liu Y; Cao G; Zhang X; Xu H; Xu H; Wang J
Int J Clin Exp Pathol; 2015; 8(6):6821-7. PubMed ID: 26261568
[TBL] [Abstract][Full Text] [Related]
2. Renal Neoplasms With Overlapping Features of Clear Cell Renal Cell Carcinoma and Clear Cell Papillary Renal Cell Carcinoma: A Clinicopathologic Study of 37 Cases From a Single Institution.
Dhakal HP; McKenney JK; Khor LY; Reynolds JP; Magi-Galluzzi C; Przybycin CG
Am J Surg Pathol; 2016 Feb; 40(2):141-54. PubMed ID: 26752401
[TBL] [Abstract][Full Text] [Related]
3. Expression of EphA2 protein is positively associated with age, tumor size and Fuhrman nuclear grade in clear cell renal cell carcinomas.
Wang L; Hu H; Tian F; Zhou W; Zhou S; Wang J
Int J Clin Exp Pathol; 2015; 8(10):13374-80. PubMed ID: 26722543
[TBL] [Abstract][Full Text] [Related]
4. Carbonic Anhydrase IX is not a predictor of outcomes in non-metastatic clear cell renal cell carcinoma - a digital analysis of tissue microarray.
Zerati M; Leite KR; Pontes-Junior J; Segre CC; Reis ST; Srougi M; Dall'Oglio MF
Int Braz J Urol; 2013; 39(4):484-92. PubMed ID: 24054396
[TBL] [Abstract][Full Text] [Related]
5. Succinate dehydrogenase B: a new prognostic biomarker in clear cell renal cell carcinoma.
Cornejo KM; Lu M; Yang P; Wu S; Cai C; Zhong WD; Olumi A; Young RH; Wu CL
Hum Pathol; 2015 Jun; 46(6):820-6. PubMed ID: 25827535
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma.
Petraki CD; Gregorakis AK; Vaslamatzis MM; Papanastasiou PA; Yousef GM; Levesque MA; Diamandis EP
Tumour Biol; 2006; 27(1):1-7. PubMed ID: 16340244
[TBL] [Abstract][Full Text] [Related]
7. Stem cell markers aldehyde dehydrogenase type 1 and nestin expressions in renal cell cancer.
Ozbek E; Calik G; Otunctemur A; Aliskan T; Cakir S; Dursun M; Somay A
Arch Ital Urol Androl; 2012 Mar; 84(1):7-11. PubMed ID: 22649953
[TBL] [Abstract][Full Text] [Related]
8. Immunoexpression of napsin A in renal neoplasms.
Zhu B; Rohan SM; Lin X
Diagn Pathol; 2015 Mar; 10():4. PubMed ID: 25889632
[TBL] [Abstract][Full Text] [Related]
9. A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade.
Paner GP; Amin MB; Alvarado-Cabrero I; Young AN; Stricker HJ; Moch H; Lyles RH
Am J Surg Pathol; 2010 Sep; 34(9):1233-40. PubMed ID: 20679882
[TBL] [Abstract][Full Text] [Related]
10. High expression of APRIL correlates with poor prognosis in clear cell renal cell carcinoma.
Lee C; Park JW; Suh JH; Moon KC
Pathol Res Pract; 2015 Nov; 211(11):824-8. PubMed ID: 26296917
[TBL] [Abstract][Full Text] [Related]
11. A promising biomarker to distinguish benign and malignant renal tumors: ELABELA.
Artas G; Kuloglu T; Dagli AF; Ugur K; Yardim M; Aydin S; Artas H; Kocdor H
Niger J Clin Pract; 2019 Mar; 22(3):386-392. PubMed ID: 30837428
[TBL] [Abstract][Full Text] [Related]
12. Significance of amyloid A immunoexpression in the prognosis of renal cell carcinoma.
Oz Atalay F; Aytac Vuruskan B; Vuruskan H
APMIS; 2016 Apr; 124(4):257-62. PubMed ID: 26750935
[TBL] [Abstract][Full Text] [Related]
13. The SWI/SNF chromatin-remodeling complex status in renal cell carcinomas with sarcomatoid or rhabdoid features.
Kinoshita F; Kohashi K; Sugimoto M; Takamatsu D; Kiyozawa D; Eto M; Oda Y
Virchows Arch; 2020 Nov; 477(5):651-660. PubMed ID: 32447490
[TBL] [Abstract][Full Text] [Related]
14. The chromophobe tumor grading system is the preferred grading scheme for chromophobe renal cell carcinoma.
Finley DS; Shuch B; Said JW; Galliano G; Jeffries RA; Afifi AA; Castor B; Magyar C; Sadaat A; Kabbinavar FF; Belldegrun AS; Pantuck AJ
J Urol; 2011 Dec; 186(6):2168-74. PubMed ID: 22014797
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis.
Leite KR; Reis ST; Junior JP; Zerati M; Gomes Dde O; Camara-Lopes LH; Srougi M
Diagn Pathol; 2015 Oct; 10():189. PubMed ID: 26470780
[TBL] [Abstract][Full Text] [Related]
16. Comparison of clinicopathological parameters with FoxM1 expression in renal cell carcinoma.
Kocarslan S; Guldur ME; Ekinci T; Ciftci H; Ozardali HI
J Cancer Res Ther; 2014; 10(4):1076-81. PubMed ID: 25579557
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of the enzyme that esterifies retinol, lecithin:retinol acyltransferase, in subtypes of human renal cancer and normal kidney.
Zhan HC; Gudas LJ; Bok D; Rando R; Nanus DM; Tickoo SK
Clin Cancer Res; 2003 Oct; 9(13):4897-905. PubMed ID: 14581364
[TBL] [Abstract][Full Text] [Related]
18. High Novel Oncogene with Kinase-Domain (NOK) Gene Expression is Associated with the Progression of Renal Cell Carcinoma.
Cao Q; Chen M; Li Z; Huang W; Jin Y; Ye X; Tong M
Clin Lab; 2016; 62(1-2):179-86. PubMed ID: 27012048
[TBL] [Abstract][Full Text] [Related]
19. Expression of serine protease matriptase in renal cell carcinoma: correlation of tissue microarray immunohistochemical expression analysis results with clinicopathological parameters.
Jin JS; Chen A; Hsieh DS; Yao CW; Cheng MF; Lin YF
Int J Surg Pathol; 2006 Jan; 14(1):65-72. PubMed ID: 16501837
[TBL] [Abstract][Full Text] [Related]
20. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.
Waldert M; Haitel A; Marberger M; Katzenbeisser D; Ozsoy M; Stadler E; Remzi M
BJU Int; 2008 Nov; 102(10):1381-4. PubMed ID: 18782311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
